Omeprazole
Omeprazole 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Active Ulcerative Colitis、Weight Management。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
9 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Hoffmann-La Roche
- Gilead Sciences
- Medical University of Gdansk
- National University Hospital, Singapore
- Tanta University
- Livzon Pharmaceutical Group Inc.
- Prof Urs Zingg
- Murdoch Childrens Research Institute
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- CVS Pharmacy
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Poland、Singapore、Egypt、中国、瑞士、澳大利亚、美国、India、丹麦、Vietnam、德国、Argentina
正在招募患者的 Omeprazole 研究
Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1
不适用招募中PolandNCT06917963Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone
IV 期招募中SingaporeNCT06690164Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
III 期招募中EgyptNCT07275827A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
III 期招募中中国NCT06850480The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass
IV 期招募中瑞士NCT05320796A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
I 期招募中澳大利亚NCT06383338Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
I 期招募中美国NCT06562907Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
IV 期招募中中国NCT07139366A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
不适用招募中IndiaNCT06953986A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
不适用招募中美国NCT05517928GMPA Versus PPI for Gastric Protection and aGVHD Risk
不适用招募中中国NCT07791849Treatment of Gastroesophageal Reflux Disease in Infants
IV 期招募中丹麦NCT06255886Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU
不适用招募中IndiaNCT07399054Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
不适用招募中VietnamNCT07260006Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial
IV 期招募中德国NCT04448028A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
III 期招募中美国Argentina澳大利亚比利时NCT05646862A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
不适用招募中中国NCT03365609Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
II 期招募中EgyptNCT07293910Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
II 期招募中美国NCT04337580An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
I 期招募中美国比利时德国PolandNCT07665723Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM
不适用招募中IndiaNCT06955520Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
I 期招募中美国NCT06733675The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
不适用招募中South KoreaNCT02373280Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy
IV 期招募中美国NCT07037888
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。